[go: up one dir, main page]

MX2022004869A - Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. - Google Patents

Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.

Info

Publication number
MX2022004869A
MX2022004869A MX2022004869A MX2022004869A MX2022004869A MX 2022004869 A MX2022004869 A MX 2022004869A MX 2022004869 A MX2022004869 A MX 2022004869A MX 2022004869 A MX2022004869 A MX 2022004869A MX 2022004869 A MX2022004869 A MX 2022004869A
Authority
MX
Mexico
Prior art keywords
vaccine
methods
chikungunya virus
particles similar
inducing
Prior art date
Application number
MX2022004869A
Other languages
English (en)
Inventor
Jeffery L Alexander
Sean Robert Bennett
Jonathan Fowler Smith
Original Assignee
Emergent Travel Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Travel Health Inc filed Critical Emergent Travel Health Inc
Publication of MX2022004869A publication Critical patent/MX2022004869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se dirige a composiciones y vacunas mejoradas de partículas similares a virus (VLP) para usarse en la inducción de una respuesta inmunitaria y/o inmunidad protectora contra una infección por el virus Chikungunya (CHIKV) en un sujeto, por ejemplo, induciendo una respuesta de anticuerpos neutralizantes contra el CHIKV en un sujeto dentro de los 7 días posteriores a la administración de una dosis única de la composición o vacuna.
MX2022004869A 2019-10-25 2020-10-26 Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. MX2022004869A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926357P 2019-10-25 2019-10-25
US202062993563P 2020-03-23 2020-03-23
PCT/US2020/057361 WO2021081499A1 (en) 2019-10-25 2020-10-26 Chikungunya virus-like particle vaccine and methods of using the same

Publications (1)

Publication Number Publication Date
MX2022004869A true MX2022004869A (es) 2022-07-27

Family

ID=75620856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004869A MX2022004869A (es) 2019-10-25 2020-10-26 Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.

Country Status (14)

Country Link
US (1) US20220409717A1 (es)
EP (1) EP4048306A4 (es)
JP (1) JP2022553299A (es)
KR (1) KR20220097422A (es)
CN (1) CN114828881A (es)
AU (1) AU2020370603A1 (es)
BR (1) BR112022007474A2 (es)
CA (1) CA3155315A1 (es)
IL (1) IL292433A (es)
MX (1) MX2022004869A (es)
PH (1) PH12022550939A1 (es)
TW (1) TW202120123A (es)
UY (1) UY38933A (es)
WO (1) WO2021081499A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
WO2025064770A2 (en) * 2023-09-20 2025-03-27 La Jolla Institute of Immunology Alphavirus t cell epitopes, megapools and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
SG171828A1 (en) * 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
UA126548C2 (uk) * 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
EP3655539A1 (en) * 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
CN108355131A (zh) * 2018-02-12 2018-08-03 江苏南农高科技股份有限公司 猪圆环病毒2d型病毒样颗粒疫苗及其制备方法

Also Published As

Publication number Publication date
EP4048306A4 (en) 2024-03-27
JP2022553299A (ja) 2022-12-22
KR20220097422A (ko) 2022-07-07
IL292433A (en) 2022-06-01
US20220409717A1 (en) 2022-12-29
EP4048306A1 (en) 2022-08-31
WO2021081499A1 (en) 2021-04-29
CA3155315A1 (en) 2021-04-29
TW202120123A (zh) 2021-06-01
AU2020370603A1 (en) 2022-05-12
BR112022007474A2 (pt) 2022-07-12
PH12022550939A1 (en) 2024-02-12
UY38933A (es) 2021-04-30
CN114828881A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
Jansen et al. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
Ko et al. Distinct effects of monophosphoryl lipid A, oligodeoxynucleotide CpG, and combination adjuvants on modulating innate and adaptive immune responses to influenza vaccination
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
AR080111A1 (es) Metodos y composiciones de inmunizacion
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
MY187472A (en) Multivalent vlp conjugates
Erdman et al. Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept
WO2015138471A1 (en) Heat inactivated poxvirus improves vaccination results
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
GT201400199A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
UY31574A1 (es) Vacunas contra la malaria
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso
Prokopenko et al. Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain